These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35149663)

  • 1. The Prescription Drug User Fee Act: Much More Than User Fees.
    Mitchell AP; Trivedi NU; Bach PB
    Med Care; 2022 Apr; 60(4):287-293. PubMed ID: 35149663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approval times for new drugs: does the source of funding for FDA staff matter?
    Carpenter D; Chernew M; Smith DG; Fendrick AM
    Health Aff (Millwood); 2003; Suppl Web Exclusives():W3-618-24. PubMed ID: 15506165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates.
    Berndt ER; Gottschalk AH; Philipson TJ; Strobeck MW
    Nat Rev Drug Discov; 2005 Jul; 4(7):545-54. PubMed ID: 16052239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prescription Drug User Fee Act of 1992 and the new drug development process.
    Kaitin KI
    Am J Ther; 1997; 4(5-6):167-72. PubMed ID: 10423607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prescription Drug User Fee Act: Cause for Concern?
    Gabay M
    Hosp Pharm; 2018 Apr; 53(2):88-89. PubMed ID: 29581600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. History, status, and politicization of the FDA.
    Wang W; Wertheimer AI
    Res Social Adm Pharm; 2022 May; 18(5):2811-2816. PubMed ID: 34215537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA's Generic Drug Program: Decreasing Time to Approval and Number of Review Cycles.
    Chazin H; Woo J; Han J; Grosser S; Luan J
    Ther Innov Regul Sci; 2020 Jul; 54(4):758-763. PubMed ID: 32557293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prescription Drug User Fee Act of 1992. A 5-year experiment for industry and the FDA.
    Shulman SR; Kaitin KI
    Pharmacoeconomics; 1996 Feb; 9(2):121-33. PubMed ID: 10160091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Explaining reductions in FDA drug review times: PDUFA matters.
    Olson MK
    Health Aff (Millwood); 2003; Suppl Web Exclusives():W4-S1-W4-S2. PubMed ID: 15506166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update to Drugs, Devices, and the FDA: How Recent Legislative Changes Have Impacted Approval of New Therapies.
    Van Norman GA
    JACC Basic Transl Sci; 2020 Aug; 5(8):831-839. PubMed ID: 32864509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Impacts of the Generic Drug User Fee Act Fee Structure.
    Dong K; Boehm G; Zheng Q
    Value Health; 2017 Jun; 20(6):792-798. PubMed ID: 28577697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA's Unimproved Enforcement of Postmarketing Requirements and Commitments: Implications for Providers and Patients.
    Dauner DG; Dauner KN; Peterson ALH
    Res Social Adm Pharm; 2020 Jun; 16(6):844-847. PubMed ID: 31812502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program.
    Galluppi GR; Ahamadi M; Bhattacharya S; Budha N; Gheyas F; Li CC; Chen Y; Dosne AG; Kristensen NR; Magee M; Samtani MN; Sinha V; Taskar K; Upreti VV; Yang J; Cook J
    Clin Pharmacol Ther; 2024 Aug; 116(2):282-288. PubMed ID: 38519861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-review deadlines and safety problems.
    Carpenter D; Zucker EJ; Avorn J
    N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extending the US Food and Drug Administration's Postmarket Authorities.
    Fernandez Lynch H; Sachs RE; Lee S; Herder M; Ross JS; Ramachandran R
    JAMA Health Forum; 2023 Jun; 4(6):e231313. PubMed ID: 37294583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval.
    Neumann PJ; Crummer E; Chambers JD; Tunis SR
    Milbank Q; 2023 Dec; 101(4):1047-1075. PubMed ID: 37644739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA reform signed into law. Food and Drug Administration.
    James JS
    AIDS Treat News; 1997 Dec; (No 284):6-7. PubMed ID: 11364915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What Commissioner Gottlieb's FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help.
    Waxman H; Corr B; Martin K; Duong S
    Issue Brief (Commonw Fund); 2018 Apr; 2018():1-10. PubMed ID: 29992802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(133):39588-611. PubMed ID: 18850675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.